In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.
PDF (713K)
Journal: 1992/September - Antimicrobial Agents and Chemotherapy
ISSN: 0066-4804
PUBMED: 1503453
Abstract:
The in vitro activity of Ro 23-9424 against bacterial isolates from patients with cancer was compared with those of fleroxacin, ciprofloxacin, cefoperazone, and ceftazidime. Ro 23-9424 inhibited the majority of the members of the family Enterobacteriaceae and all Aeromonas isolates at a concentration of less than or equal to 1.0 micrograms/ml. It was also active against Acinetobacter spp. and Haemophilus influenzae, including beta-lactamase-producing strains. The MIC for 90% of isolates (MIC90) of Pseudomonas aeruginosa was 16.0 micrograms/ml. All group A and B streptococci were inhibited by less than or equal to 0.25 micrograms/ml, and 90% of group G streptococci and Streptococcus pneumoniae were inhibited by 1.0 micrograms/ml. All methicillin-susceptible strains of Staphylococcus aureus and 60% of methicillin-resistant strains were susceptible to 2.0 micrograms of Ro 23-9424 per ml, whereas the MIC90 for Staphylococcus epidermidis and Staphylococcus hominis isolates was 4.0 micrograms/ml. Staphylococcus haemolyticus and Enterococcus spp. were less susceptible; MIC90s for them were 16.0 and 32.0 micrograms/ml. Ro 23-9424 has a broad antibacterial spectrum and potential utility for therapy of infections in cancer patients.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(7)
References
(16)
Diseases
(1)
Drugs
(3)
Chemicals
(3)
Organisms
(2)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Antimicrob Agents Chemother 36(4): 879-882
PMID: 1503453

In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.

Abstract

The in vitro activity of Ro 23-9424 against bacterial isolates from patients with cancer was compared with those of fleroxacin, ciprofloxacin, cefoperazone, and ceftazidime. Ro 23-9424 inhibited the majority of the members of the family Enterobacteriaceae and all Aeromonas isolates at a concentration of less than or equal to 1.0 micrograms/ml. It was also active against Acinetobacter spp. and Haemophilus influenzae, including beta-lactamase-producing strains. The MIC for 90% of isolates (MIC90) of Pseudomonas aeruginosa was 16.0 micrograms/ml. All group A and B streptococci were inhibited by less than or equal to 0.25 micrograms/ml, and 90% of group G streptococci and Streptococcus pneumoniae were inhibited by 1.0 micrograms/ml. All methicillin-susceptible strains of Staphylococcus aureus and 60% of methicillin-resistant strains were susceptible to 2.0 micrograms of Ro 23-9424 per ml, whereas the MIC90 for Staphylococcus epidermidis and Staphylococcus hominis isolates was 4.0 micrograms/ml. Staphylococcus haemolyticus and Enterococcus spp. were less susceptible; MIC90s for them were 16.0 and 32.0 micrograms/ml. Ro 23-9424 has a broad antibacterial spectrum and potential utility for therapy of infections in cancer patients.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (713K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
icon of scanned page 879
879
icon of scanned page 880
880
icon of scanned page 881
881
icon of scanned page 882
882

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Beskid G, Fallat V, Lipschitz ER, McGarry DH, Cleeland R, Chan K, Keith DD, Unowsky J. In vitro activities of a dual-action antibacterial agent, Ro 23-9424, and comparative agents. Antimicrob Agents Chemother. 1989 Jul;33(7):1072–1077.[PMC free article] [PubMed] [Google Scholar]
  • Bodey GP. Antibiotics in patients with neutropenia. Arch Intern Med. 1984 Sep;144(9):1845–1851. [PubMed] [Google Scholar]
  • Bodey GP. Infection in cancer patients. A continuing association. Am J Med. 1986 Jul 28;81(1A):11–26. [PubMed] [Google Scholar]
  • Christenson JG, Chan KK, Cleeland R, Dix-Holzknecht B, Farrish HH, Jr, Patel IH, Specian A. Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals. Antimicrob Agents Chemother. 1990 Oct;34(10):1895–1900.[PMC free article] [PubMed] [Google Scholar]
  • Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med. 1987 Jan;106(1):7–11. [PubMed] [Google Scholar]
  • Georgopapadakou NH, Bertasso A, Chan KK, Chapman JS, Cleeland R, Cummings LM, Dix BA, Keith DD. Mode of action of the dual-action cephalosporin Ro 23-9424. Antimicrob Agents Chemother. 1989 Jul;33(7):1067–1071.[PMC free article] [PubMed] [Google Scholar]
  • Gu JW, Neu HC. In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics. Antimicrob Agents Chemother. 1990 Feb;34(2):189–195.[PMC free article] [PubMed] [Google Scholar]
  • Jones P, Bodey GP, Rolston K, Fainstein V, Riccardi S. Cefoperazone plus mezlocillin for empiric therapy of febrile cancer patients. Am J Med. 1988 Jul 25;85(1A):3–8. [PubMed] [Google Scholar]
  • Jones RN, Barry AL, Thornsberry C. Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime. Antimicrob Agents Chemother. 1989 Jun;33(6):944–950.[PMC free article] [PubMed] [Google Scholar]
  • Karp JE, Merz WG, Hendricksen C, Laughon B, Redden T, Bamberger BJ, Bartlett JG, Saral R, Burke PJ. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1987 Jan;106(1):1–7. [PubMed] [Google Scholar]
  • Meunier F, Zinner SH, Gaya H, Calandra T, Viscoli C, Klastersky J, Glauser M. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother. 1991 May;35(5):873–878.[PMC free article] [PubMed] [Google Scholar]
  • Piccart M, Klastersky J, Meunier F, Lagast H, Van Laethem Y, Weerts D. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother. 1984 Dec;26(6):870–875.[PMC free article] [PubMed] [Google Scholar]
  • Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, Gress J, Longo D, Marshall D, McKnight J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986 Aug 28;315(9):552–558. [PubMed] [Google Scholar]
  • Rolston KV, Nguyen H, Messer M, LeBlanc B, Ho DH, Bodey GP. In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients. Antimicrob Agents Chemother. 1990 Nov;34(11):2263–2266.[PMC free article] [PubMed] [Google Scholar]
  • Viscoli C, Van der Auwera P, Meunier F. Gram-positive infections in granulocytopenic patients: an important issue? J Antimicrob Chemother. 1988 Apr;21 (Suppl 100):149–156. [PubMed] [Google Scholar]
  • Winston DJ, Ho WG, Nakao SL, Gale RP, Champlin RE. Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med. 1986 May;80(5):884–890. [PubMed] [Google Scholar]
Department of Medical Specialties, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Department of Medical Specialties, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Copyright notice
Abstract
The in vitro activity of Ro 23-9424 against bacterial isolates from patients with cancer was compared with those of fleroxacin, ciprofloxacin, cefoperazone, and ceftazidime. Ro 23-9424 inhibited the majority of the members of the family Enterobacteriaceae and all Aeromonas isolates at a concentration of less than or equal to 1.0 micrograms/ml. It was also active against Acinetobacter spp. and Haemophilus influenzae, including beta-lactamase-producing strains. The MIC for 90% of isolates (MIC90) of Pseudomonas aeruginosa was 16.0 micrograms/ml. All group A and B streptococci were inhibited by less than or equal to 0.25 micrograms/ml, and 90% of group G streptococci and Streptococcus pneumoniae were inhibited by 1.0 micrograms/ml. All methicillin-susceptible strains of Staphylococcus aureus and 60% of methicillin-resistant strains were susceptible to 2.0 micrograms of Ro 23-9424 per ml, whereas the MIC90 for Staphylococcus epidermidis and Staphylococcus hominis isolates was 4.0 micrograms/ml. Staphylococcus haemolyticus and Enterococcus spp. were less susceptible; MIC90s for them were 16.0 and 32.0 micrograms/ml. Ro 23-9424 has a broad antibacterial spectrum and potential utility for therapy of infections in cancer patients.
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.